6 Out 2020 | News
U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. TP-102 is a cocktail of five bacteriophages that is being developed for the topical treatment of diabetic foot ulcers against Staphylococcus aureus,...
17 Ago 2020 | News
In 2019, Technophage was among the top 100 companies with the highest R&D investment in Portugal. According to the provisional results of the IPCTN19, the 100 companies or groups with more intramural investment in R&D are responsible for 47% of the total...
9 Jul 2020 | News
TechnoPhage owns an innovative unit for the production of biological medicines that has now obtained authorization from INFARMED for the manufacture and analysis of medicines, becoming one of the few in the country with this capacity. The unit established in Venda...
6 Abr 2020 | News
COVID-19 New Challenge: joint effort to mitigate world’s pandemic crisis (TechnoPhage S.A., Faculty of Pharmacy of University of Lisbon and Vector B2B – Drug Developing Association for Research in Biotechnology) In Portugal, we have highly qualified human resources...
4 Abr 2020 | News
Since the 1st January 2020, Technophage is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the...
